Given the complexity of the TME and the interplay between various immune markers, elucidating the relationship between SIGLEC9 expression and tumor characteristics could significantly enhance our understanding of its prognostic value and potential as a therapeutic target. This evidence concerns the gene SIGLEC9 and neoplasm.